Cellectar Biosciences Inc Cash Flow Conversion Efficiency
Cellectar Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Cellectar Biosciences Inc (CLRB) has a cash flow conversion efficiency ratio of -0.438x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.34 Million) by net assets ($9.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cellectar Biosciences Inc (2004–2025)
Cash flow conversion efficiency of Cellectar Biosciences Inc from 2004 to 2025. This chart illustrates how Cellectar Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Cellectar Biosciences Inc for real-time trading data and today's change.
Cellectar Biosciences Inc Cash Flow Conversion Ratio Explained
Cellectar Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cellectar Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectar Biosciences Inc ranked by their cash flow conversion efficiency. Also see Cellectar Biosciences Inc (CLRB) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agri-Tech (India) Limited
NSE:AGRITECH
|
-0.010x |
|
ROKMASTER Resources Corp
V:RKR
|
0.203x |
|
Trinity Biotech plc
NASDAQ:TRIB
|
0.022x |
|
Automobile &Pc
KO:015260
|
0.067x |
|
PT Winner Nusantara Jaya Tbk
JK:WINR
|
-0.010x |
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
-0.155x |
|
FBS Global Limited Ordinary Shares
NASDAQ:FBGL
|
N/A |
|
Inca Minerals Ltd
AU:ICG
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Cellectar Biosciences Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cellectar Biosciences Inc from 2004 to 2025. Review Cellectar Biosciences Inc (CLRB) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.92 Million | $-23.12 Million | -2.331x | +29.98% |
| 2024-12-31 | $14.29 Million | $-47.58 Million | -3.329x | -241.64% |
| 2023-12-31 | $-13.78 Million | $-32.38 Million | 2.350x | +188.84% |
| 2022-12-31 | $9.54 Million | $-25.22 Million | -2.645x | -287.30% |
| 2021-12-31 | $33.05 Million | $-22.57 Million | -0.683x | -168.60% |
| 2020-12-31 | $54.79 Million | $-13.93 Million | -0.254x | +80.30% |
| 2019-12-31 | $9.06 Million | $-11.69 Million | -1.291x | -49.60% |
| 2018-12-31 | $13.26 Million | $-11.44 Million | -0.863x | +15.80% |
| 2017-12-31 | $10.75 Million | $-11.02 Million | -1.025x | -67.52% |
| 2016-12-31 | $13.54 Million | $-8.28 Million | -0.612x | +87.71% |
| 2015-12-31 | $1.65 Million | $-8.21 Million | -4.978x | -505.11% |
| 2014-12-31 | $10.75 Million | $-8.84 Million | -0.823x | +84.73% |
| 2013-12-31 | $1.70 Million | $-9.15 Million | -5.387x | -730.95% |
| 2012-12-31 | $10.16 Million | $-6.59 Million | -0.648x | -2.95% |
| 2011-12-31 | $9.48 Million | $-5.97 Million | -0.630x | +90.26% |
| 2010-12-31 | $1.21 Million | $-7.80 Million | -6.468x | -1738.29% |
| 2009-12-31 | $-26.90 Million | $-10.62 Million | 0.395x | -87.28% |
| 2008-12-31 | $-5.58 Million | $-17.33 Million | 3.104x | +35.27% |
| 2007-12-31 | $-5.87 Million | $-13.47 Million | 2.294x | +476.26% |
| 2006-12-31 | $10.61 Million | $-6.47 Million | -0.610x | -20.00% |
| 2005-12-31 | $4.72 Million | $-2.40 Million | -0.508x | -667.81% |
| 2004-12-31 | $-4.35 Million | $-389.18K | 0.089x | -- |
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more